NVO Jun 2024 90.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

39.00

0.00

(0.00%)

As of 10:24AM EDT. Market open.

Loading interactive chart…

Zacks
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.
Zacks
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
Zacks
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.